See more : Blue Room Acquisition Corp. Unit (IBLUU) Income Statement Analysis – Financial Results
Complete financial analysis of Gemina Laboratories Ltd. (GLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gemina Laboratories Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- XDC Industries (Shenzhen) Limited (300615.SZ) Income Statement Analysis – Financial Results
- 1867 Western Financial Corporation (WFCL) Income Statement Analysis – Financial Results
- Quick-Med Technologies, Inc. (QMDT) Income Statement Analysis – Financial Results
- Reconstruction Capital II Limited (RC2.L) Income Statement Analysis – Financial Results
- Grindwell Norton Limited (GRINDWELL.NS) Income Statement Analysis – Financial Results
Gemina Laboratories Ltd. (GLABF)
About Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 93.37K | 50.28K | 43.83K | 12.09K |
| Gross Profit | -93.37K | -50.28K | -43.83K | -12.09K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.48M | 4.15M | 2.71M | 508.26K |
| General & Administrative | 2.14M | 1.80M | 1.99M | 141.23K |
| Selling & Marketing | 462.32K | 0.00 | 0.00 | 125.11K |
| SG&A | 2.61M | 1.80M | 1.99M | 125.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.09M | 5.98M | 4.73M | 633.51K |
| Cost & Expenses | 5.09M | 5.98M | 4.73M | 645.60K |
| Interest Income | 0.00 | 1.10K | 0.00 | 0.00 |
| Interest Expense | 19.26K | 0.00 | 539.00 | 2.47K |
| Depreciation & Amortization | 21.71K | 50.28K | 43.83K | 12.09K |
| EBITDA | -5.18M | -5.93M | -4.69M | -633.51K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -5.98M | -4.73M | -645.60K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -130.91K | 280.97K | 175.98K | -251.41K |
| Income Before Tax | -5.22M | -5.98M | -4.73M | -834.15K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -117.61K | -184.65K | 0.00 |
| Net Income | -5.22M | -5.98M | -4.73M | -834.15K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.10 | -0.10 | -0.02 |
| EPS Diluted | -0.07 | -0.10 | -0.10 | -0.02 |
| Weighted Avg Shares Out | 72.45M | 60.19M | 47.66M | 50.24M |
| Weighted Avg Shares Out (Dil) | 72.45M | 60.19M | 47.66M | 50.24M |
Gemina Laboratories Announces Private Placement
Gemina Laboratories Strategic Update
Source: https://incomestatements.info
Category: Stock Reports